GeneDx (NASDAQ:WGS) CEO Sells $1,319,347.20 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 17,179 shares of GeneDx stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $76.80, for a total transaction of $1,319,347.20. Following the sale, the chief executive officer owned 58,447 shares in the company, valued at approximately $4,488,729.60. This represents a 22.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, March 4th, Katherine Stueland sold 25,459 shares of GeneDx stock. The shares were sold at an average price of $78.61, for a total transaction of $2,001,331.99.
• On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The shares were sold at an average price of $94.00, for a total transaction of $155,382.00.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $73.00 on Friday. The firm has a market cap of $2.14 billion, a PE ratio of -97.33 and a beta of 2.03. The firm’s fifty day moving average is $91.35 and its 200-day moving average is $119.33. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. GeneDx Holdings Corp. has a 52 week low of $55.17 and a 52 week high of $170.87.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $120.99 million during the quarter, compared to the consensus estimate of $120.80 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%. Sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Institutional Investors Weigh In On GeneDx

A number of large investors have recently bought and sold shares of WGS. Jones Financial Companies Lllp raised its holdings in shares of GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of GeneDx in the 4th quarter valued at about $27,000. Quarry LP grew its stake in shares of GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after buying an additional 209 shares during the period. Ramirez Asset Management Inc. bought a new stake in GeneDx in the 4th quarter valued at about $33,000. Finally, Greenline Wealth Management LLC bought a new stake in GeneDx in the 4th quarter valued at about $33,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on WGS shares. Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a research report on Monday, February 23rd. Canaccord Genuity Group lifted their price objective on GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Wells Fargo & Company upgraded GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price on the stock in a research report on Monday, February 9th. Finally, BTIG Research decreased their target price on GeneDx from $200.00 to $170.00 and set a “buy” rating for the company in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $150.71.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.